NEW HOPE, Penn.–(BUSINESS WIRE)–VerdePharmHealth, the nation’s premier provider of comprehensive cannabis solutions – group purchasing organization, clinical solutions, and healthcare technology, today announced a strategic partnership with Strain Genie, to leverage its market leadership in cannabis DNA testing and proprietary algorithm that examines over 450 DNA biomarkers to provide personalized genetic analysis and real-world patient insights. Another key focus of the partnership will be real-world evidence studies focused on CINV and pain in 2020.
“VerdePharmHealth will leverage this strategic alliance with Strain Genie to further enhance our unique end-to-end solution and healthcare provider knowledge base via valuable genetic testing and personalized insights that affect cannabis use and patient’s health. Strain Genie’s proprietary algorithm and most comprehensive cannabis-health report will play a pivotal role towards managing appropriate provider interventions and informed engagement during a patient’s journey,” said Jesse Hollingsworth, founder & chief executive officer at VerdePharmHealth.
“We believe that partnering with VerdePharmHealth, an emerging leader in the medical cannabis space, offers the potential to significantly advance personalized cannabis DNA testing. Personalization is an integral, yet missing component of current cannabis-based care,” said Nicco Regente, chief executive officer at Strain Genie. “This exclusive GPO channel partnership further solidifies our mission of generating real-world evidence to accelerate and improve personalized DNA testing. The proceedings of this partnership stand to substantially increase the global standard of care for evaluating a patient response to cannabis interventions and provides physicians with much-needed insights to identify optimal recommendations for patients.”
VerdePharmHealth, the first organization of its kind in the U.S., provides comprehensive multi-specialty group purchasing, clinical, and healthcare technology solutions designed to drive high-level commitment and affordability for members through accessibility of quality cannabis products from prequalified distributors and manufacturers and leveraging of clinical services and robust technology to improve decisions for interventions at the point of care and monitor real-world evidence. Utilizing retrospective data and clinical studies for decision-support and standardization of appropriate-use in the care delivery process is a central pillar towards achieving outcomes. For more information, visit www.verdepharmhealth.com or follow VerdePharmHealth on LinkedIn.
About Strain Genie:
Strain Genie provides a genetic analysis service that looks at over 450 biomarkers to generate the world’s most comprehensive and personalized Cannabis Wellness Report. Strain Genie’s reports are filled with insights surrounding how a consumer’s body should metabolically respond to CBD and provide data-driven recommendations for other cannabinoids and terpenes found in CBD products. The CBD Report contains information about an individual’s predisposition to a number of different conditions and connects consumers to cannabinoids, terpenes, and products that peer-reviewed literature has shown to be effective in supporting general wellness.
Matters discussed in this release that are not statements of historical or current facts, such as expected savings and other expected benefits to members and suppliers, as discussed herein, are “forward-looking statements” which may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of VerdePharmHealth and its subsidiaries and Strain Genie to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to VerdePharm and Strain Genie’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside VerdePharm and Strain Genie’s control. Forward-looking statements speak only as of the date they are made. VerdePharm nor Strain Genie undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.